What is the effect of Raloxifene (Evista) on the risk of invasive breast cancer?

• A. Increases risk
• B. Reduces risk
• C. Has no effect
• D. Depends on dosage

Answer: (B)

Raloxifene, marketed as Evista, is a selective estrogen receptor modulator (SERM) that has been shown to play a role in reducing the risk of invasive breast cancer. This medication is primarily used in postmenopausal women to prevent osteoporosis, but its impact on breast cancer risk is a significant aspect of its therapeutic profile.

Clinical studies have demonstrated that Raloxifene reduces the incidence of invasive breast cancer by antagonizing estrogen's effects on breast tissue. While estrogen can promote the growth of some breast cancers, Raloxifene acts to block these effects in breast tissue, thereby reducing the risk of developing estrogen receptor-positive invasive breast cancers.

The data supporting this effect is robust, demonstrating that women taking Raloxifene experienced lower rates of breast cancer compared to those who were not treated with the medication. This benefit of reducing breast cancer risk adds an important dimension to the therapeutic uses of Raloxifene, particularly in populations at higher risk for osteoporosis and breast cancer.

Overall, Raloxifene is a critical agent in both the prevention of osteoporosis and the reduction of breast cancer risk, making it a multifaceted option for managing women's health after menopause.